Expression, mutation, and methylation of cereblon‐pathway genes at pre‐ and post‐lenalidomide treatment in multiple myeloma. Issue 4 (12th March 2020)

• Record Type: Journal Article
• Authors: Tachita, Takuto; Kinoshita, Shiori; Ri, Masaki; Aoki, Sho; Asano, Arisa; Kanamori, Takashi; Yoshida, Takashi; Totani, Haruhito; Ito, Asahi; Kusumoto, Shigeru; Komatsu, Hirokazu; Yamagata, Kazufumi; Kubo, Kohmei; Tohkin, Masahiro; Fukuda, Shinsaku; Iida, Shinsuke
• Is Part Of: Cancer science. Volume 111:Issue 4(2020)
• Page Start: 1333
• Page End: 1343
• Publication Date: 2020-03-12
• Subjects: CRBN -- IKZF1 -- KPNA2 -- lenalidomide -- multiple myeloma; Cancer -- Periodicals; Neoplasms -- Periodicals; Research -- Periodicals; Electronic journals; 616.994005
• DOI: 10.1111/cas.14352
• Languages: English
• ISSNs: 1347-9032

Abstract

Abstract: Cereblon (CRBN) is a target for immunomodulatory drugs. This study investigated the prognostic value of the expression of CRBN‐pathway genes on the clinical relevance of lenalidomide (Len) treatment and evaluated the levels of CRBN‐binding proteins and mutations in these genes after Len treatment. Forty‐eight primary multiple myeloma cells were collected prior to treatment with Len and dexamethasone (Ld) and 25 paired samples were obtained post‐Ld therapy. These tumor cells were used to determine the expression and mutated forms of the CRBN‐pathway genes. Following normalization with CRBN levels, there was a significantly reduced IKZF1/CRBN ratio in samples that responded poorly to Ld therapy. Moreover, patients with low ratios of IKZF1/CRBN showed a significantly shorter progression‐free survival (PFS) and overall survival (OS) than those with higher ratios. However, patients with high ratios of KPNA2/CRBN showed a significantly shorter PFS and OS than patients with lower ratios. Of the 25 paired samples analyzed, most samples showed a reduction in the expression of CRBN and an increase in IKZF1 gene expression. No mutations were observed in CRBN, IKZF1, or CUL4A genes in the post‐Ld samples. In conclusion, a decreased expression of IKZF1 and increased expression of KPNA2 compared to that of CRBN mRNA predicts poor outcomes of Ld therapy. Abstract : This study investigated the prognostic value of the expression of cereblon (CRBN)‐pathway genes on the clinical relevance of lenalidomide treatment and evaluated the levels of CRBN‐binding proteins, mutations in these genes, and the methylation status of the CRBN promoter sequence. In conclusion, a decreased expression of IKZF1 and increased expression of KPNA2 compared to that of CRBN mRNA predicts poor outcomes of lenalidomide and dexamethasone therapy.